Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Structural basis of the human NAIP/NLRC4 inflammasome assembly and pathogen sensing.
Journal: Nature structural & molecular biology
Published: February 16, 2023
A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.
Journal: BMJ open gastroenterology
Published: April 09, 2021
A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: October 21, 2020
Publisher Correction: RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice.
Journal: Nature metabolism
Published: October 09, 2020
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.
Journal: ACS medicinal chemistry letters
Published: June 20, 2020
Receptor-interacting protein 1 kinase inhibition therapeutically ameliorates experimental T cell-dependent colitis in mice.
Journal: Cell death & disease
Published: December 19, 2019
Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study.
Journal: Clinical pharmacology and therapeutics
Published: October 28, 2019
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.
Journal: Journal of medicinal chemistry
Published: July 03, 2019
T Cell- and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically Ill Patients and in Patients with Cancer.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: May 17, 2019
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.
Journal: Journal of medicinal chemistry
Published: April 24, 2019
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.
Journal: ACS medicinal chemistry letters
Published: March 15, 2019
Last Updated: 09/26/2026